NewEdge Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

NewEdge Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-200	Closed	-$456	–	3977
2024 Q2	$456	Hold	200	–	–	﹤0.01%	3574
2024 Q1	$864	Hold	200	–	–	﹤0.01%	3525
2023 Q4	$610	Hold	200	–	–	﹤0.01%	3517
2023 Q3	$288	Hold	200	–	–	﹤0.01%	3296
2023 Q2	$498	Hold	200	–	–	﹤0.01%	3315
2023 Q1	$536	Hold	200	–	–	﹤0.01%	3233
2022 Q4	$1	Buy	+200	New	+$1.68K	﹤0.01%	4058

NewEdge Advisors's GTHX Position: Q3 2024 in Review

NewEdge Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 200 shares — an estimated $456 sold.

NewEdge Advisors first reported a position in GTHX in Q4 2022 and held it in 7 quarters. The position peaked at $864 in Q1 2024. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

NewEdge Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
NewEdge Advisors sold 200 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $456.
NewEdge Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2022 and held it in 7 quarters.
NewEdge Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $864 in Q1 2024.
0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.

Based on NewEdge Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.